scholarly journals Changes in Motor Unit Loss and Axonal Regeneration Rate in Sporadic and Familiar Amyotrophic Lateral Sclerosis (ALS) — Possible Different Pathogenetic Mechanisms?

10.5772/56561 ◽  
2013 ◽  
Author(s):  
Tommaso Bocci ◽  
Elisa Giorli ◽  
Lucia Briscese ◽  
Silvia Tognazzi ◽  
Fabio Giannini ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Motor Unit ◽  
Axonal Regeneration ◽  
Regeneration Rate ◽  
Pathogenetic Mechanisms ◽  
Lateral Sclerosis

scholarly journals Motor Unit Number Estimation in Neuromuscular Disease

2008 ◽  
Vol 35 (2) ◽  
pp. 153-159 ◽  
Author(s):  
Omid Rashidipour ◽  
K. Ming Chan
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Motor Unit ◽  
Neuromuscular Disease ◽  
Muscular Atrophy ◽  
Neuromuscular Diseases ◽  
Neuronal Loss ◽  
Response To Treatment ◽  
Motor Unit Number Estimation ◽  
Electrophysiological Method ◽  
Lateral Sclerosis

Motor unit number estimation (MUNE) is an electrophysiological method designed to quantify motor unit loss in target muscles of interest. Most of the techniques are noninvasive and are therefore well suited for longitudinal monitoring. In this brief review, we describe the more commonly used techniques and their applications in amyotrophic lateral sclerosis, poliomyelitis, spinal muscular atrophy and hereditary sensorimotor neuropathies. Findings in some of these studies offer important pathophysiological insights. Since conventional electrophysiologic methods are not sensible measures of motor neuronal loss, MUNE could play a potentially important role in the diagnosis, monitoring of disease progression and response to treatment in neuromuscular diseases in which motor unit loss is a major feature.

Motor unit hyperexcitability in amyotrophic lateral sclerosis vs amino acids acting as neurotransmitters

2002 ◽  
Vol 106 (1) ◽  
pp. 34-38 ◽  
Author(s):  
A. Kostera-Pruszczyk ◽  
I. Niebroj-Dobosz ◽  
B. Emeryk-Szajewska ◽  
A. Karwańska ◽  
K. Rowińska-Marcińska
Keyword(s):  
Amino Acids ◽  
Amyotrophic Lateral Sclerosis ◽  
Motor Unit ◽  
Lateral Sclerosis

scholarly journals Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons

2018 ◽  
Vol 4 (10) ◽  
pp. eaat5847 ◽  
Author(s):  
Tatsuya Osaki ◽  
Sebastien G. M. Uzel ◽  
Roger D. Kamm
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Motor Unit ◽  
Motor Neurons ◽  
Neuromuscular Junctions ◽  
Research Effort ◽  
Muscle Contractions ◽  
Drug Candidates ◽  
Chip Technology ◽  
Sporadic Als ◽  
Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease involving loss of motor neurons (MNs) and muscle atrophy, still has no effective treatment, despite much research effort. To provide a platform for testing drug candidates and investigating the pathogenesis of ALS, we developed an ALS-on-a-chip technology (i.e., an ALS motor unit) using three-dimensional skeletal muscle bundles along with induced pluripotent stem cell (iPSC)–derived and light-sensitive channelrhodopsin-2–induced MN spheroids from a patient with sporadic ALS. Each tissue was cultured in a different compartment of a microfluidic device. Axon outgrowth formed neuromuscular junctions on the muscle fiber bundles. Light was used to activate muscle contraction, which was measured on the basis of pillar deflections. Compared to a non-ALS motor unit, the ALS motor unit generated fewer muscle contractions, there was MN degradation, and apoptosis increased in the muscle. Furthermore, the muscle contractions were recovered by single treatments and cotreatment with rapamycin (a mechanistic target of rapamycin inhibitor) and bosutinib (an Src/c-Abl inhibitor). This recovery was associated with up-regulation of autophagy and degradation of TAR DNA binding protein–43 in the MNs. Moreover, administering the drugs via an endothelial cell barrier decreased the expression of P-glycoprotein (an efflux pump that transports bosutinib) in the endothelial cells, indicating that rapamycin and bosutinib cotreatment has considerable potential for ALS treatment. This ALS-on-a-chip and optogenetics technology could help to elucidate the pathogenesis of ALS and to screen for drug candidates.

Sign in / Sign up

Export Citation Format

Share Document